Section Arrow
AGIO.NASDAQ
- Agios Pharmaceuticals
Quotes are at least 15-min delayed:2025/08/31 21:40 EDT
Regular Hours
Last
 37.71
-0.47 (-1.23%)
Day High 
38.78 
Prev. Close
38.18 
1-M High
40.1 
Volume 
502.79K 
Bid
37.76
Ask
45
Day Low
37.38 
Open
38.35 
1-M Low
26.7517 
Market Cap 
2.22B 
Currency USD 
P/E 3.38 
%Yield -- 
10-SMA 37.77 
20-SMA 36.97 
50-SMA 37.05 
52-W High 62.58 
52-W Low 23.415 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
11.29/-7.60
Enterprise Value
2.26B
Balance Sheet
Book Value Per Share
23.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
36.50M
Operating Revenue Per Share
0.41
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Quotes are at least 15-min delayed:2025/08/31 21:40 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.